Relative Bioavailability of Empagliflozin Tablets After Different Administration Modi in Healthy Male and Female Subjects (Randomised, Two-period Crossover Study)
Latest Information Update: 01 Oct 2025
At a glance
- Drugs Empagliflozin (Primary)
- Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; Decompensated heart failure; Gestational diabetes; Heart failure; Insulin resistance; Kidney disorders; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 18 Sep 2025 Status changed from active, no longer recruiting to completed.
- 29 Aug 2025 Planned End Date changed from 7 Jul 2025 to 14 Sep 2025.
- 05 Aug 2025 Planned End Date changed from 30 Jun 2025 to 7 Jul 2025.